CGON (CG Oncology, Inc. Common stock)
Insider Trading Activity
Every open-market purchase and sale reported by CGON officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | LEONARD E POST | Director | MIXED | — | — |
| 2026-07-17 | LEONARD E POST | Director | MIXED | — | — |
| 2026-07-14 | James Mulay | Director | MIXED | — | — |
| 2026-06-29 | Brian Guan-Chyun Liu | Director | Buy | — | — |
| 2026-06-25 | LEONARD E POST | Director | MIXED | — | — |
| 2026-06-23 | LEONARD E POST | Director | MIXED | — | — |
| 2026-06-16 | James Mulay | Director | MIXED | — | — |
| 2026-06-05 | James Mulay | Director | A | — | — |
| 2026-06-05 | Susan E Graf | Director | A | — | — |
| 2026-06-05 | LEONARD E POST | Director | MIXED | — | — |
| 2026-06-05 | Victor Edward Jr Tong | Director | A | — | — |
| 2026-06-05 | Brian Guan-Chyun Liu | Director | A | — | — |
| 2026-06-05 | Christina Rossi | Director | A | — | — |
| 2026-04-20 | James Mulay | Director | MIXED | — | — |
| 2026-04-16 | Joshua F. Patterson | See Remarks | A | — | — |
| 2026-04-16 | Vijay Kasturi | Chief Medical Officer | A | — | — |
| 2026-04-16 | Arthur Kuan | Chief Executive Officer | A | — | — |
| 2026-04-16 | JAMES M. DETORE | Chief Financial Officer | A | — | — |
| 2026-04-16 | Ambaw Bellete | President and COO | A | — | — |
| 2026-03-17 | James Mulay | Director | MIXED | — | — |
| 2026-03-13 | Arthur Kuan | Chief Executive Officer | MIXED | — | — |
| 2026-03-06 | Arthur Kuan | Chief Executive Officer | MIXED | — | — |
| 2026-01-13 | James Mulay | Director | MIXED | — | — |
| 2025-11-26 | Christina Rossi | Director | A | — | — |
| 2025-11-18 | LEONARD E POST | Director | MIXED | — | — |
| 2025-10-15 | LEONARD E POST | Director | MIXED | — | — |
| 2025-10-10 | James Mulay | Director | MIXED | — | — |
| 2025-10-01 | LEONARD E POST | Director | MIXED | — | — |
| 2025-09-30 | James Mulay | Director | MIXED | — | — |
| 2025-09-22 | James Mulay | Director | MIXED | — | — |
| 2025-09-16 | LEONARD E POST | Director | MIXED | — | — |
| 2025-09-15 | Brian Guan-Chyun Liu | Director | Buy | — | — |
| 2025-09-08 | James Mulay | Director | MIXED | — | — |
| 2025-09-04 | Hong Fang Song | Director | Sell | — | — |
| 2025-09-04 | LEONARD E POST | Director | MIXED | — | — |
| 2025-07-18 | LEONARD E POST | Director | MIXED | — | — |
| 2025-06-06 | Hong Fang Song | Director | A | — | — |
| 2025-06-06 | James Mulay | Director | A | — | — |
| 2025-06-06 | LEONARD E POST | Director | A | — | — |
| 2025-06-06 | Victor Edward Jr Tong | Director | A | — | — |
| 2025-06-06 | Susan E Graf | Director | A | — | — |
| 2025-06-06 | Brian Guan-Chyun Liu | Director | A | — | — |
| 2025-05-22 | LEONARD E POST | Director | MIXED | — | — |
| 2025-04-29 | LEONARD E POST | Director | MIXED | — | — |
| 2025-04-16 | Vijay Kasturi | Chief Medical Officer | A | — | — |
| 2025-04-16 | Ambaw Bellete | President and COO | A | — | — |
| 2025-04-16 | Arthur Kuan | Chief Executive Officer | A | — | — |
| 2025-04-16 | Corleen M. Roche | CFO | A | — | — |
| 2025-04-16 | Joshua F. Patterson | See Remarks | A | — | — |
| 2025-03-18 | LEONARD E POST | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,958,812 | — |
| — | 10%+ Owner | 4,958,810 | — |
| — | Director | 3,517,959 | — |
| — | Director | 1,886,236 | — |
| — | Chief Executive Officer | 200,763 | — |
| — | CFO | 2,000 | — |
| — | Chief Medical Officer | 1,315 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CGON quote page; the site-wide leaderboard is on the insider transactions hub.